AMG 334 CGRP antibody for migraine: time to celebrate?

被引：8
|
作者：
Ramos, Marta L. [1 ,2 ]
Pascual, Julio [3 ,4 ]
机构：
[1] Hosp Occidente Kennedy, Dept Neurol, Bogota, Colombia
[2] Univ La Sabana, Bogota, Colombia
[3] Univ Hosp Marques Valdecilla, Santander 39008, Spain
[4] IDIVAL, Santander 39008, Spain
来源：
LANCET NEUROLOGY | 2016年 / 15卷 / 04期
关键词：
GENE-RELATED PEPTIDE; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; PHASE; 2B; EFFICACY; SAFETY; TOLERABILITY; CIRCULATION; MULTICENTER;
D O I：
10.1016/S1474-4422(16)00040-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：347 / 349
页数：4
相关论文
共 50 条
  • [1] AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
    Xu, C.
    Shi, L.
    Rao, S.
    King, C.
    Sun, H.
    Zhu, D.
    Lehto, S.
    Wild, K.
    Immke, D.
    JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [2] AMG 334, the First Potent and Selective Human Monoclonal Antibody Antagonist Against the CGRP Receptor
    King, L.
    Rao, S.
    King, C.
    Sun, H.
    Zhu, D.
    Lehto, S.
    Wild, K.
    Immke, D.
    Xu, C.
    HEADACHE, 2014, 54 (08): : 1417 - 1418
  • [3] EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
    C Xu
    L Shi
    S Rao
    C King
    H Sun
    D Zhu
    S Lehto
    K Wild
    D Immke
    The Journal of Headache and Pain, 2014, 15
  • [4] Exposure-Response of Erenumab (AMG 334) in Episodic Migraine Patients
    Vu, Thuy
    Kuchimanchi, Mita
    Wu, Liviawati
    Clements, John D.
    Kahn, Joseph
    Mikol, Daniel
    Lee, Edward
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S81 - S81
  • [5] Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
    Ashina, Messoud
    Dodick, David
    Goadsby, Peter J.
    Reuter, Uwe
    Silberstein, Stephen
    Zhang, Feng
    Gage, Julia R.
    Cheng, Sunfa
    Mikol, Daniel D.
    Lenz, Robert A.
    NEUROLOGY, 2017, 89 (12) : 1237 - 1243
  • [6] CGRP signalling in migraine: time to look downstream?
    Levy, Dan
    BRAIN, 2023, 146 (12) : 4796 - 4798
  • [7] Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine
    Lu, Lingyun
    Liu, Meijun
    Hu, Songshan
    Liu, Yao
    Yang, Dongdong
    Hong, Peiwei
    DRUGS OF THE FUTURE, 2017, 42 (10) : 609 - 615
  • [8] CGRP-antibody; a potential therapeutic tool in migraine treatment
    Edvinsson, Lars
    Jansen-Olesen, Inger
    Juhl, Louise
    Olesen, Jes
    CEPHALALGIA, 2007, 27 (06) : 611 - 611
  • [9] Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries
    Ohlsson, Lena
    Haanes, Kristian A.
    Kronvall, Erik
    Xu, Cen
    Snellman, Josefin
    Edvinsson, Lars
    CEPHALALGIA, 2019, 39 (14) : 1745 - 1752
  • [10] CGRP and migraine
    Cauchi, M.
    Robertson, N. P.
    JOURNAL OF NEUROLOGY, 2016, 263 (01) : 192 - 194
12345